STOCK TITAN
  1. Home
  2. News
  3. VCNX

Vaccinex, Inc. - VCNX STOCK NEWS

Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.

Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company headquartered in Rochester, NY. Specializing in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines, and other biologic products, Vaccinex is dedicated to addressing serious diseases with unmet medical needs, including cancer, multiple sclerosis, and other autoimmune diseases.

The company is pioneering a unique approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). Vaccinex's leading drug candidate, pepinemab, is designed to block SEMA4D, a potent agent believed to prevent immune infiltration into tumors and reduce inflammation in chronic brain diseases. Currently, pepinemab is undergoing evaluation in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease. Additionally, there is ongoing exploration for potential Phase 3 development in Huntington's disease.

Vaccinex conducts research both in-house and through collaborations with prominent academic institutions and biotechnology firms. The company's proprietary drug discovery platform, ActivMAb, plays a significant role in its innovative drug development approach. The development team at Vaccinex comprises experienced industry veterans skilled in therapeutic biologics research, manufacturing, quality control, toxicology, pharmacology, regulatory affairs, and clinical affairs.

Recently, Vaccinex has achieved notable milestones, including a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards and the advancement of its clinical trials. The company continues to secure funding for its research, with significant investments from the Alzheimer’s Drug Discovery Foundation and grants from the Alzheimer’s Association.

Vaccinex remains committed to advancing its clinical programs and expanding its pipeline of innovative therapies to improve patient outcomes in challenging diseases.

News

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Vaccinex, Inc. announced financial results and clinical updates, including progress on pepinemab for Alzheimer's Disease and Head and Neck Cancer. Topline data for the Phase 1/2a SIGNAL-AD study is expected in Q3 2024, with $17.9 million raised in new financing. Pepinemab targets SEMA4D, a key player in neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
earnings
-
News

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary
Vaccinex, Inc. announced a registered direct offering and concurrent private placement of 193,000 shares of common stock with warrants, priced at $7.77 per share. The company aims to raise funds for its innovative approach to treating Alzheimer's disease and cancer through SEMA4D inhibition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
offering
-
News

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

Rhea-AI Summary
Vaccinex, Inc. announces eight new antibody discovery agreements utilizing its ActivMAb platform to select antibodies against challenging transmembrane protein targets. The company has partnered with major pharma and biotech companies and antibody service providers to accelerate drug discovery. The ActivMAb system allows for the development of antibodies targeting complex protein targets crucial for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
none
News

Vaccinex, Inc. Announces Reverse Stock Split

Rhea-AI Summary
Vaccinex, Inc. (VCNX) announces a 1-for-14 reverse stock split to regain Nasdaq compliance. Stockholders approved the split to meet the $1.00 minimum bid price requirement. The split aims to ensure the closing bid price remains above $1.00 for 10 consecutive business days by March 4, 2024. The reverse stock split will not affect total authorized shares or ownership percentages but will combine every fourteen shares into one share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
stock split
-
News

Vaccinex Announces Pricing of $3.7 Million PIPE Financing

Rhea-AI Summary
Vaccinex, Inc. announces a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors. The offering includes the sale of 3,838,544 shares of common stock and 1,265,078 common stock equivalents, together with common warrants to purchase up to 5,103,622 shares of common stock. The offering is expected to close on or before February 8, 2024, and the gross proceeds are expected to be $3.7 million. The financing, along with other commitments, is anticipated to fully fund the ongoing SIGNAL-AD trial through the release of topline data in the third quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
none
-
News

Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule

Rhea-AI Summary
Vaccinex, Inc. (Nasdaq: VCNX) has reassured Nasdaq of actions it plans to take to meet the minimum bid price requirement. The company has been granted an exception until March 4, 2024, to address this issue. Vaccinex is also on schedule to complete the treatment for a randomized phase 2 study in Alzheimer’s disease by June 2024, with a focus on potential near-term catalysts and key endpoints including brain metabolic activity and treatment effects on cognition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.74%
Tags
none
News

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Vaccinex, Inc. (Nasdaq: VCNX) Achieves Full Accrual in Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease, Raises Over $10 Million in New Financing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
earnings
-
News

Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

Rhea-AI Summary
Vaccinex, Inc. will be presenting novel findings for its lead product, pepinemab, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The studies demonstrate that pepinemab induces the formation of lymphoid structures in tumors, which promote efficient immune responses and improved outcomes to immune checkpoint inhibitors. In the Phase 2 KEYNOTE-B84 study, pepinemab in combination with Merck's anti-PD-1 therapy showed a doubling of objective responses and progression-free survival in patients with hard-to-treat tumors. Another study with collaborators at Emory University showed that pepinemab in combination with nivolumab and/or ipilimumab induced tertiary lymphoid structures in tumors, resulting in ongoing response in 8 out of 8 patients for more than 2 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
clinical trial
-
News

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Rhea-AI Summary
Vaccinex reports positive findings for its lead product, pepinemab, in treating brain inflammation. The drug significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, indicating its potential to reverse harmful astrocyte activation. A randomized, placebo-controlled trial is currently underway to test the drug's effectiveness in Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
none
News

Vaccinex Announces Pricing of $9.6 Million Public Offering

Rhea-AI Summary
Vaccinex, Inc. announces securities purchase agreements for the sale of 9.6M shares of common stock and warrants, expected to raise $9.6M in gross proceeds. The funds will be used for the development of its lead drug candidate and other corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.17%
Tags
offering

FAQ

What is the current stock price of Vaccinex (VCNX)?

The current stock price of Vaccinex (VCNX) is $3.16 as of November 15, 2024.

What is the market cap of Vaccinex (VCNX)?

The market cap of Vaccinex (VCNX) is approximately 9.5M.

What is Vaccinex, Inc.?

Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing therapeutic antibodies, vaccines, and biologic products to treat serious diseases, including cancer and autoimmune diseases.

Where is Vaccinex, Inc. located?

Vaccinex, Inc. is based in Rochester, NY.

What is Vaccinex's lead drug candidate?

Vaccinex's lead drug candidate is pepinemab, which targets semaphorin 4D (SEMA4D) and is being studied for its potential to treat cancer and neurodegenerative diseases.

What is the focus of Vaccinex's research?

Vaccinex focuses on treating serious diseases with unmet medical needs, such as cancer, multiple sclerosis, and other autoimmune diseases.

What clinical studies is pepinemab involved in?

Pepinemab is currently being evaluated in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease.

What is the ActivMAb platform?

ActivMAb is Vaccinex's proprietary drug discovery platform that aids in the development of its innovative therapeutic products.

Who are Vaccinex's research partners?

Vaccinex collaborates with world-class academic institutions and biotechnology companies for its discovery research.

What recent milestone has Vaccinex achieved?

Vaccinex recently completed a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards.

How is Vaccinex funded?

Vaccinex has received significant investments and grants, including funding from the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association.

Who leads the development team at Vaccinex?

Vaccinex's development team is led by experienced industry veterans with expertise in various fields such as therapeutic biologics research, manufacturing, and regulatory affairs.

Stock VCNX logo
Vaccinex, Inc.

Nasdaq:VCNX

VCNX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

VCNX Stock Data

9.53M
2.80M
9.37%
48.64%
1.23%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ROCHESTER